文献速递浆细胞疾病

RPL5位于1p22.1在多发性骨髓瘤中反复缺失且其表达与硼替佐米疗效相关

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.
PubMed 文献 · Leukemia · 2016-12-02

研究通过高分辨率基因组分析将多发性骨髓瘤1p22缺失区缩小至58 kb最小缺失区,涵盖EVI5和RPL5两个基因。EVI5和RPL5低mRNA表达与诊断病例更差生存相关。复发患者中RPL5而非EVI5 mRNA水平在硼替佐米应答者中显著更低,硼替佐米治疗可克服其不良预后使无进展生存期升至与高RPL5表达患者相当。

要点

  • 1p22.1最小缺失区为58 kb,仅包含EVI5和RPL5两个基因。
  • EVI5和RPL5低mRNA表达与诊断病例更差生存相关。
  • RPL5 mRNA表达可能是复发患者硼替佐米初始应答的生物标志物。

核心结论

  • 遗传数据将1p22最小缺失区限定于EVI5和RPL5,二者促进多发性骨髓瘤进展的作用尚待确定。
  • RPL5 mRNA表达被确定为复发患者对硼替佐米初始应答的生物标志物及新诊断和复发患者长期治疗后生存获益的标志物。

研究设计与样本

  • 研究采用高分辨率基因组分析界定1p22.1最小缺失区,并分析诊断和复发多发性骨髓瘤病例的基因表达与生存。

主要发现

  • 1p22.1最小缺失区为58 kb,涵盖EVI5和RPL5两个基因。
  • 诊断病例中EVI5和RPL5低mRNA表达与更差生存相关。
  • 1p22缺失患者EVI5和RPL5 mRNA表达更低,但1p22缺失状态在部分病例中不能预测RPL5表达,提示其他机制下调RPL5表达。
  • 复发患者中对硼替佐米应答者RPL5而非EVI5 mRNA水平显著更低。
  • 新诊断和复发患者中,硼替佐米治疗可通过提高无进展生存期至与高RPL5表达患者相当来克服其不良预后。

局限性

  • EVI5和RPL5在多发性骨髓瘤进展中的作用尚待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chromosomal region 1p22 is deleted in ⩾20% of multiple myeloma (MM) patients, suggesting the presence of an unidentified tumor suppressor. Using high-resolution genomic profiling, we delimit a 58 kb minimal deleted region (MDR) on 1p22.1 encompassing two genes: ectopic viral integration site 5 (EVI5) and ribosomal protein L5 (RPL5). Low mRNA expression of EVI5 and RPL5 was associated with worse survival in diagnostic cases. Patients with 1p22 deletion had lower mRNA expression of EVI5 and RPL5, however, 1p22 deletion status is a bad predictor of RPL5 expression in some cases, suggesting that other mechanisms downregulate RPL5 expression. Interestingly, RPL5 but not EVI5 mRNA levels were significantly lower in relapsed patients responding to bortezomib and; both in newly diagnosed and relapsed patients, bortezomib treatment could overcome their bad prognosis by raising their progression-free survival to equal that of patients with high RPL5 expression. In conclusion, our genetic data restrict the MDR on 1p22 to EVI5 and RPL5 and although the role of these genes in promoting MM progression remains to be determined, we identify RPL5 mRNA expression as a biomarker for initial response to bortezomib in relapsed patients and subsequent survival benefit after long-term treatment in newly diagnosed and relapsed patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hofman IJF, van Duin M, De Bruyne E, et al. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia. 2016. PMID: 27909306. doi:10.1038/leu.2016.370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。